EGFR and cholangiocarcinoma: Clapéron et al. observed that in a xenograft model of CCA cells coinjected with primary human liver myofibroblasts, treatment with gefitinib (an inhibitor of EGFR tyrosine kinase activity) reduced tumor growth and angiogenesis as compared to vehicle-treated mice [83].